Edition:
United States

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

39.00USD
20 Jul 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$39.00
Open
$38.90
Day's High
$39.20
Day's Low
$38.40
Volume
217,847
Avg. Vol
335,679
52-wk High
$42.80
52-wk Low
$14.40

Chart for

About

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $2,806.09
Shares Outstanding(Mil.): 71.95
Dividend: --
Yield (%): --

Financials

  HRTX.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -3.46 -- --
ROI: -163.21 -3.65 13.18
ROE: -205.20 -5.62 15.09

BRIEF-Heron Therapeutics Reports Quarterly Loss Per Share Of $0.81

* HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2018 AND RECENT CORPORATE PROGRESS

May 10 2018

BRIEF-Heron Therapeutics Announces Pricing Of Underwritten Public Offering

* HERON THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

Mar 28 2018

BRIEF-Heron Therapeutics Announces Proposed Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 28 2018

BRIEF-Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials Of HTX-011 In Bunionectomy And Hernia Repair

* HERON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIALS OF HTX-011 IN BUNIONECTOMY AND HERNIA REPAIR

Mar 19 2018

BRIEF-Heron Therapeutics Qtrly Net Loss Per Share $1.09

* HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

Feb 27 2018

Competitors

Earnings vs. Estimates